$GNPX's technologies bridge a critical gap by combining with targeted therapies to provide treatments to large patient populations who would otherwise not be candidates for targeted therapies. They hold a portfolio of 30 issued and 2 pending patents covering our technologies and targeted molecular therapies.

Our research and development is focused around better understanding cancer immuno-biology so that we can identify patients who will respond well to certain drugs. This is the premise of personalized medicine, whereby certain cancer molecular profiles can be specific targets for drugs and biologics. https://www.genprex.com/technology